11/20/2013

The FDA has agreed to review Nektar Therapeutics' new drug application for naloxegol as a treatment for opioid-induced constipation. Naloxegol is intended for patients with chronic non-cancer pain who regularly take opioid painkillers. The move triggers a $70 million milestone fee from partner AstraZeneca.

Related Summaries